Bayer Looks To Turn Aleve Around Following Negative Media Hit
This article was originally published in The Tan Sheet
Executive Summary
Press coverage of a halted NIH study that called into question the cardiovascular safety of naproxen will cause an approximate $30 mil. decline in first-quarter U.S. Aleve sales, according to Bayer